5 $10 Stocks That Will Triple

2. Caribou Biosciences, Inc. (NASDAQ:CRBU)

Number of Hedge Fund Holders: 23

Share Price as of February 26: $6.94

Caribou Biosciences, Inc. (NASDAQ:CRBU) is a clinical-stage biopharmaceutical company focused on developing genome-edited allogeneic cell therapies for hematologic malignancies and solid tumors. It is one of the stocks that are set to triple. On November 22, 2023, the U.S. FDA granted orphan drug designation to Caribou Biosciences, Inc. (NASDAQ:CRBU)’s experimental CAR-T-cell therapy for multiple myeloma. This designation makes Caribou eligible for incentives, including tax credits, fee waivers, and seven years of US marketing exclusivity, as it advances its allogeneic anti-BCMA CAR-T cell therapy (CB-011) in a Phase 1 trial for relapsed or refractory multiple myeloma. 

According to Insider Monkey’s fourth quarter database, 23 hedge funds were bullish on Caribou Biosciences, Inc. (NASDAQ:CRBU), compared to 21 funds in the prior quarter. Christopher Medlock James’ Partner Fund Management is the leading stakeholder of the company, with 6.48 million shares worth over $37 million.